Pentadeca Arginate (PDA) + Capromorelin stack
A research-context overview of stacking Pentadeca Arginate (PDA) with Capromorelin: the rationale, complementary benefits, side-effect overlap, and pharmacokinetic considerations. Educational only — never a recommendation.
Why this stack?
Pairing a Performance peptide like Capromorelin with a Recovery peptide like Pentadeca Arginate (PDA) is one of the most common stack archetypes in the research literature. The Performance compound drives the GH/IGF-1 axis or anabolic signaling; the Recovery compound shortens the soft-tissue and inflammation tax of training, letting the anabolic signal land on healthier tissue. The two work on independent pathways, so timing concerns are minimal — most researchers dose them on separate clocks.
Pentadeca Arginate (PDA)
Arginate-salt analog of BPC-157 developed for improved injection stability and tissue repair.
Key benefits
- ✓Tendon and ligament healing
- ✓Better stability than BPC-157 acetate
- ✓Anti-inflammatory
Side effects to watch
- ⚠Injection-site irritation
- ⚠Limited human trial data
Capromorelin
Oral non-peptide ghrelin-receptor agonist; FDA-approved as a veterinary appetite stimulant.
Key benefits
- ✓Stimulates appetite
- ✓Raises GH/IGF-1
- ✓Oral bioavailability
Side effects to watch
- ⚠Hypersalivation (in dogs/cats)
- ⚠Mild emesis
- ⚠Lethargy
Half-life considerations
Reference half-life data for one or both of these compounds is not in our table — see the individual peptide profiles for cited PK ranges.
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.